The BCL6 gene encodes a zinc-finger transcription factor and is altered by chromosomal rearrangements in its 5' noncoding region in '30% of diffuse large-cell lymphoma (DLCL). We report here that, in 22/30 (73%) DLCL and 7/15 (47%) follicular lymphoma (FL), but not in other tumor types, the BCL6 gene is also altered by multiple (1.4 x 10-3-1.6 x 10-2 per bp), often biallelic, mutations clustering in its 5' noncoding region. These mutations are of somatic origin and are found in cases displaying either normal or rearranged BCL6 alleles indicating their independence from chromosomal rearrangements and linkage to immunoglobulin genes. These alterations identify a mechanism of genetic instability in malignant B cells and may have been selected during lymphomagenesis for their role in altering BCL6 expression. Sequencing Procedures. PCR products E1.10, E1.11, and E1.12 were subjected to direct sequence analysis as described (21). In addition, a unique PCR product encompassing the same genomic region (nucleotides +413 to + 1141), amplified by primers E1.21C (upstream; 5'-ATGCTTTGGCTCCAA-GTT-3') and E1.26 (downstream; 5'-CACGATACTTCA-TCTCATC-3'), annealing temperature = 54°C, was subcloned into the pGEM-T vector (Promega), and DNA minipreps (Wizard DNA purification system, Promega) were sequenced using forward and reverse primers with the ABI373A DNA sequencer (Perkin-Elmer, Applied Biosystems Division).
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Diffuse large-cell lymphoma (DLCL) accounts for 30-40% of all non-Hodgkin lymphoma (NHL) cases and often represents the final transformation stage of follicular lymphoma (FL) (1). Chromosomal translocations involving chromosome band 3q27 are found in 8-12% of NHL cases (2, 3) and have been shown to involve the BCL6 gene (4, 5) , also called LAZ3 (6) or BCL5 (7) (for a review, see ref. 8) . Several 
studies have
shown that BCL6 rearrangements occur with an overall frequency of 30-40% in DLCL and 6-14% in FL and can be found in cases without cytogenetically detectable 3q27 abnormalities (9-11). BCL6 rearrangements are associated with a subset of DLCL characterized by extranodal presentation and favorable clinical outcome (12) .
The BCL6 gene encodes for a protein containing six Cterminal zinc-finger motifs homologous to members of the Kruppel subfamily of zinc-finger proteins (13) . The N-terminal portion of BCL6 contains a ZiN (for Zinc-finger N-terminal)/ POZ (POx/Zinc-finger) domain that is found in other Drosophila and mammalian zinc-finger proteins as well as in some poxvirus proteins (14) . The BCL6 gene is expressed in mature B cells within germinal centers, but not in immature B-cell precursors or in differentiated plasma cells (5, 7, 8, 15) . The structural features and the pattern of expression of the BCL6 protein suggest that it may function as a DNA-binding transcription factor, presumably involved in the control of B-cell differentiation and lymphoid organ development.
In DLCL and FL, chromosomal rearrangements affecting the BCL6 gene cluster within a 4-kb region spanning the promoter and the first noncoding exon. In most cases, the chromosomal breakpoints are located immediately 3' to the first exon and cause the juxtaposition of BCL6 exons 2-10 (spanning the entire coding domain) downstream to heterologous promoters derived from other chromosomes (5, 8, 11 abnormal chromosomal band 3q27, the site of the BCL6 gene (4).
BCL6 sequences representing exons 2-10 and spanning the entire coding region of the gene were examined by PCR/SSCP analysis using the set of primers illustrated in Fig. 1 . No SSCP variants were observed in these sequences in 22 DLCL cases tested (data not shown). Thus, in agreement with a recent report (11), we concluded that mutations in BCL6 coding sequences do not occur at any appreciable frequency in NHL.
In contrast, a large number of SSCP variant patterns was detected in a 3.5-kb region spanning the first noncoding exon ( Fig. 1 ) in many NHL cases (Table 1 for a summary of the data; Fig. 2 for representative PCR/SSCP results). A subset of these variants was classified as germ-line polymorphisms since they were recurrent (homozygous or heterozygous) in 22 control DNAs from Epstein-Barr virus-immortalized LCLs established from peripheral blood lymphocytes of healthy individuals (PCR fragments E1.2, E1.5, E1.6, E1.11, E1.12, E1.13; Fig. 2 for examples). An additional 71 variant SSCP patterns were noted which were unique to individual tumor DNAs. These variants were distributed in 29 tumor cases (64%), including 73% of DLCL and 47% of FL. These cases included tumors carrying unrearranged BCL6 genes (63%) as well as 7/10 tumors carrying a rearranged BCL6 allele (Table 1 ). In the latter cases, the allele affected by the mutation(s) was not identified. However, the presence of a biallelic SSCP variant in a case with a single rearranged BCL6 allele (not shown) indicated that mutations could occur on the rearranged as well as the unrearranged allele in some cases. Although most SSCP variants (67/71) were heterozygous with retention of the normal allele, homozygous shifts with little representation of the normal allele (most likely from normal DNA contaminating the tumor biopsy) were also observed in 4/71 cases, suggesting either the loss or the mutation of the second allele (see below). (Fig. 2) . Thus, most of the mutations affecting BCL6 were of somatic origin and associated with DLCL and FL. BJAB; 3, LY1; 4, 1468; 5, 1462; 6, 1774; 7, 1780; 8, 1683; 9, 1576; 10, 1779; 11, 1652; 12, 1773; 13, 1688; 14, 1785; 15, 1783; 16, 1784; 17-19 Fig. 3) . A two-step approach was followed in order to obtain information on the nature, of the mutations as well as their allelic distribution. For each case, the PCR products E1.10, E1.11, and E1.12 were subjected to direct sequencing; a single PCR product spanning the same three regions was then subcloned into plasmid and at least four independent subclones were sequenced. In the 10 cases studied, a total of 59 alterations was detected by direct PCR sequencing including single base-pair substitutions (n = 55), small deletions (n = 3), and one insertion ( Table 2 for a summary of data; Fig. 4 for representative results). For each tumor case studied, all PCR fragments which appeared abnormal by SSCP analysis were found to contain mutations by DNA sequencing; in addition, in 4 cases, PCR products which appeared normal by SSCP analysis were found tA, Deletion.
to contain mutations upon sequencing, confirming the limited sensitivity of the SSCP assay. All mutations found by direct sequencing of the PCR products were found in the subcloned products where they were distributed in one or two subcloned alleles ( Table 2 ), suggesting that they derived from a single clonal population and that no major subclonal variation was present in the tumor biopsies. Four additional mutations (distributed in 4 cases), which were not detectable by direct PCR sequencing, were found in subcloned products; however, none of these 4 mutations was confirmed upon analysis of additional (4) clones derived from an independent PCR reaction, suggesting that they might have been caused by Taq polymerase errors. In 4 of 10 cases both alleles carried mutations, although all mutations were heterozygous (Table 2 ; Fig. 4 for an example). No bias in the type of single base-pair substitution was detected (not shown), although the number of mutations studied may not be sufficient for statistically informative analysis. The number of lesions per allele was variable, ranging between 1 and 12 over 730 bp analyzed, corresponding to an incidence of 1.4 x 10-3-1.6 x 10-2 per bp.
BCL6 Is Not Mutated in Other Tumor Types. To determine whether the observed BCL6 mutations were specific for NHL, a panel of 123 nonhematologic tumor cases was screened for mutations in the sequences most frequently mutated in NHL (E1.10, E1.11, E1.12; Representative results of direct sequencing of PCR product E1.10 in two DLCL cases are shown. Arrows point to mutations. Shown below the autoradiograms is the chromatogram generated by automatic sequencing of the same fragments after cloning into plasmid. Note that all mutations detected by direct sequencing are found after cloning and are distributed in two alleles (tumor 1468) with each mutation being heterozygous. NHL including 73% DLCL and 47% FL. Since this region was previously shown to be involved in chromosomal rearrangements in a smaller fraction of the same tumors (33% DLCL, 0% FL; Fig. 3 ), our findings indicate that the same domain of the BCL6 gene can be altered by different types of alterations. Mutations and rearrangements can occur independently in different tumor cases or concomitantly in the same tumor. Considering their combined frequencies, the underestimated frequency of mutated cases due to the limited sensitivity of the SSCP assay, and the incomplete definition of the 3' boundary of the mutated region (see Fig. 3 represent a locus-specific somatic hypermutation event occurring in the absence of physical linkage to antigen receptor loci. The mechanism underlying BCL6 mutations is unknown. These mutations may result from a defect in a DNA repair mechanism which, however, must be distinct from the DNA mismatch repair pathway defective in various solid tumors (27) since the same NHL cases used for this study lack microsatellite instability (unpublished results), the molecular hallmark of defects in DNA mismatch repair enzymes (28). In addition, the mechanism causing BCL6 mutations does not seem to involve the short-patch DNA repair enzymes that correct the deaminationassociated G-T mispairs (29), since these mismatches were not preferentially observed among BCL6 mutations in NHL.
Conversely, several observations suggest that BCL6 mutations may be the result of the IgV hypermutation mechanism acting on non-Ig loci. First, the frequency of BCL6 mutations (0.14-1.6 x 10-2 per bp) is unusually high and comparable only to that observed for hypermutated IgV genes in B cells (0.4-10.6 x 10-2; refs. 30-32). In particular, the frequency of BCL6 mutations in the most heavily mutated cases approaches that observed in the most mutated V sequences in antigenselected IgG-producing B cells (33) suggesting that BCL6 mutations may also be under selective pressure. Second, BCL6 mutations are specifically associated with tumors such as DLCL and FL, which derive from mature B cells within germinal centers, the site where IgV sequences undergo somatic hypermutation (33, 34). Finally, although the relatively small sample studied prevented the detection of a significant bias in transitions versus transversions and strand polarity (35), which often characterize mutated IgV genes, the rare detection of small deletions and insertions is also consistent with the involvement of the IgV somatic hypermutation mechanism (36).
A recent study has reported that non-Ig sequences can be targeted by somatic B-cell-specific hypermutation in an experimental system in transgenic mice (37). Although, at variance with BCL-6, the non-Ig sequences were embedded in an Ig gene, the two sets of results may be related. In fact, BCL-6 mutations may represent the first naturally occurring example of an ectopic activity of the hypermutation mechanism involving sequences which display no homology with IgV genes. If this is the case, it remains to be determined whether BCL6 mutations derive from a tumor-associated misfunction or a normal, presently unrecognized, activity of the IgV hypermutation mechanism on sequences outside the Ig loci. The absence of BCL6 mutations in nontumorigenic B cells (LCL; Fig. 2 ) does not allow us to exclude the latter hypothesis since these cells also lack IgV hypermutation due to their immature pregerminal center phenotype (18). The two hypotheses (abnormal versus normal activity of the IgV hypermutation mechanism) can be discriminated by comparative analysis of the frequency of mutations within IgV versus BCL6 sequences in purified normal germinal center B cells (34). Regardless of the nature of the mechanism involved, the existence of hypermutation events in non-Ig sequences identifies a mechanism of genetic instability with general implications for lymphomagenesis. In fact, if hypermutation can occur outside Ig loci, BCL6 may be only one of many possible targets of physiologic or pathologic significance.
The frequency, tumor association, and clustering of BCL6 mutations strongly suggest that they may have been selected based on their functional role during tumorigenesis. The genomic sequences most frequently involved in the mutations are adjacent to the BCL6 promoter region and may therefore contain regulatory signals for transcription. Notably, the region involved in the mutations also represents the major cluster of chromosomal breakpoints and is either truncated or removed in most rearranged BCL6 alleles in NHL (5, 9, 11). Thus, mutations and rearrangements may be selected for their ability to alter this region which may be important for the normal regulation of BCL6, possibly its down-regulation during differentiation of B cells into plasma cells (8, 15 
